Drug intelligence / Profile preview

levornidazole disodium phosphate

Development stage
Unknown
Lead developer
Yangtze River Pharmaceutical Group
Modality
Small Molecules
Administration
Intravenous
01

Overview

Levornidazole disodium phosphate is a **water-soluble intravenous formulation** of levornidazole, the L-isomer phosphate salt derivative of ornidazole and a member of the nitroimidazole class of anti-infective agents[7][6][9]. It is used primarily for the **treatment and prevention of infections caused by anaerobic bacteria**, including intra-abdominal, pelvic, oral, surgical, brain infections, as well as sepsis and bacteremia[7][3][1]. Levornidazole acts as a DNA-modulating agent, disrupting DNA synthesis in susceptible microorganisms[9]. Compared to ornidazole and L-ornidazole, its phosphate disodium form offers markedly improved water solubility, less vascular irritation, and minimal central nervous system suppression[7][6]. It is administered intravenously, especially when oral nitroimidazoles are unsuitable or less effective[1][7]. First approved in China in May 2021[9], it is developed and manufactured primarily by Chinese pharmaceutical companies.

Brand names
新锐
Other names
levornidazole phosphate disodiumlevo-ornidazole disodium phosphate
02

Targets

Neuraminidase

Beyond the preview

Go deeper on levornidazole disodium phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levornidazole disodium phosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call